Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00391586 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
A Phase 2 study, sponsored by New Mexico Cancer Research Alliance.
- Terminated
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00391586 is a Phase 2 study that was terminated before completion, run by New Mexico Cancer Research Alliance. The registered enrollment target is 45 participants.
The verdict
NCT00391586, a Phase 2 study, was terminated before completion, sponsored by New Mexico Cancer Research Alliance.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historical controls.
Interventions
- DRUG Platinum-based chemotherapy
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00391586
The ClinicalTrials.gov registry entry for NCT00391586 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Platinum-based chemotherapy is the first listed.
NCT00391586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00391586 about?
NCT00391586 is a clinical study titled "Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung". This study was conducted to compare the activities of erlotinib to that of intravenous, platinum-based therapy in the treatment of non-small cell lung cancer (NSCLC). The goal of this trial was to demonstrate clinical equivalence of erlotinib to platinum-based frontline therapy, compared to historic...
What is the current status of trial NCT00391586?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-07. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00391586?
The interventions under investigation include: Platinum-based chemotherapy (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00391586?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.